What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.”In the company’s words, NCT06369298 on ClinicalTrials.gov
- Tested for
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Main trialPhase 2
- “This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.”In the company’s words, NCT06369298 on ClinicalTrials.gov
Other drugs for Heart Failure With Reduced Ejection Fraction
- Balcinrenone/ dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- HiCM-188HELP Therapeutics Co., Ltd. · Phase 3
- Omecamtiv MecarbilCytokinetics · Phase 3
- InclisiranNovartis Pharmaceuticals · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Oct 2026 | Study of JK07 in Patients With Chronic Heart Failure | |
| Phase 2Withdrawn | 16 Apr 2026 | Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension | |
| Phase 1Withdrawn | 26 May 2023 | Single-Ascending Dose Study of JK07 in Subjects With HFpEF | |
| Phase 1Completed | 8 Jun 2023 | Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026